Caja Costarricense del Seguro Social
San José, Provincia de San José, 40901, Costa Rica
NCT Number: NCT07448428
The goal of this observational registry study is to characterize the clinical, epidemiological, and therapeutic features of patients with generalized pustular psoriasis (GPP) in Costa Rica through a standardized national registry. The main question it aims to answer is:
What are the clinical, epidemiological, and therapeutic characteristics of patients with generalized pustular psoriasis registered in the country, and how do these relate to disease severity and evolution?
Patients with GPP receiving routine dermatologic care in participating centers will have their demographic, clinical, severity, comorbidity, and treatment data recorded using a standardized case report form. Clinical assessments (e.g., GPPASI, PASI/BSA, DLQI), laboratory results, triggers, complications, and therapies will be documented and updated during periodic follow-up visits as part of usual care.
Trial opening soon.
Get NotifiedAll sexes
Observational
San José, Provincia de San José, 40901, Costa Rica
Generalized pustular psoriasis (GPP) is a rare, severe, and potentially life-threatening inflammatory dermatosis characterized by recurrent flares of sterile pustules on erythematous skin with systemic involvement. In Costa Rica and much of Latin America, the absence of structured epidemiologic and clinical data has limited understanding of disease burden, phenotypic patterns, triggers, comorbidities, and real-world therapeutic outcomes. This has contributed to diagnostic delays, heterogeneous management, and uncertainty regarding optimal use of systemic and biologic therapies.
To address this gap, a national observational registry has been established within the Costa Rican Social Security health system to systematically collect standardized longitudinal data on patients with confirmed GPP. The registry captures information generated during routine dermatologic care without altering clinical management. Data are entered in a structured case report form aligned with international GPP research standards and include demographics, clinical phenotype, disease course, severity indices (e.g., GPPASI, PASI/BSA, DLQI), laboratory markers, comorbidities, identified triggers, and details of systemic and biologic treatments and their outcomes. Periodic follow-up enables evaluation of disease evolution, treatment persistence, dose modifications, adverse events, and complications over time.
The registry is designed to generate the first national dataset on GPP, enabling characterization of prevalence, regional distribution, severity patterns, and therapeutic responses in the local population. Standardized data collection is expected to improve comparability across centers, support development of evidence-based national management strategies, and facilitate participation in international collaborative research networks focused on rare and severe psoriasis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 5 years
Characterized by frequency of flares, presence of systemic complications, and need for hospitalization during follow-up, as recorded in standardized registry visits.
Time frame: 5 years
Assessed by the Generalized Pustular Psoriasis Area and Severity Index (GPPASI) recorded during routine clinical evaluations.
Time frame: 5 years
Change from baseline in Generalized Pustular Psoriasis Area and Severity Index score as a measure of clinical severity over time.
Time frame: 5 years
Change from baseline in percentage of Body Surface Area affected by psoriasis.
Time frame: 5 years
Incidence of adverse events and serious adverse events considered related to systemic or biologic therapies.
Time frame: 5 years
Proportion of patients receiving each category of therapy, including conventional systemic agents, biologic agents, and targeted therapies. Distribution of treatment types will be expressed as percentages of the total treated population.
Time frame: 5 years
Assessed by the PASI (Psoriasis Area Severity Index) recorded during routine clinical evaluations.
Time frame: 5 years
Change from baseline in Psoriasis Area and Severity Index score as a measure of cutaneous disease severity.
Trial opening soon.
Get NotifiedCaja Costarricense de Seguro Social
Other Gov
National Registry of Patients With Generalized Pustular Psoriasis Treated Within the Costa Rican Social Security System
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06013969
Generalized Pustular Psoriasis, Psoriasis
Irvine, California, United States
View Trial DetailsNCT03886246
Generalized Pustular Psoriasis, Psoriasis
Auburn Hills, Michigan, United States
View Trial DetailsNCT06295692
Erythrodermic Psoriasis, Generalized Pustular Psoriasis
Hokkaido, Japan
View Trial DetailsNCT06100991
Generalized Pustular Psoriasis, Psoriasis
Waltham, Massachusetts, United States
View Trial Details